Bibliography
- Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev 2014;27(3):441-62
- Sandkovsky U, Vargas L, Florescu DF. Adenovirus: current epidemiology and emerging approaches to prevention and treatment. Curr Infect Dis Rep 2014;16(8):416
- Lion T, Kosulin K, Landlinger C, et al. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia 2010;24(4):706-14
- Lugthart G, Oomen MA, Jol-van der Zijde CM, et al. The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution. Biol Blood Marrow Transplant 2015;21(2):293-9
- Florescu DF, Keck MA. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev Anti-infect Ther 2014;12(10):1171-8
- Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005;191(3):396-9
- Toth K, Spencer JF, Dhar D, et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008;105(20):7293-7
- Tollefson AE, Spencer JF, Ying B, et al. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Res 2014;112:38-46
- Paolino K, Sande J, Perez E, et al. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. J Clin Virol 2011;50(2):167-70
- Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012;18(5):731-8
- Grimley M, Papanicolaou G, Maron G, et al. Improved Outcomes in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients Treated with Brincidofovir for Disseminated Adenovirus AdV) Disease Compared to Literature: Updated Preliminary Results from the AdVise (CMX001-304) Study. 41st Annual Meeting of the European Society for Blood and Marrow Transplantation; Istanbul, Turkey; 2015
- Grimley M, Maron G, Prasad V, et al. Preliminary Results from the AdVise Study Evaluating Brincidofovir (BCV, CMX001) for the Treatment of Disseminated and High-Risk Adenovirus (AdV) Infection. Bone Marrow Transplant Tandem Meetings; San Diego, CA; 2015
- Khanna R, Smith C. Cellular immune therapy for viral infections in transplant patients. Indian J Med Res 2013;138(5):796-807
- Feucht J, Opherk K, Lang P, et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015;125(12):1986-94
- Geyeregger R, Freimuller C, Stevanovic S, et al. Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS One 2013;8(4):e59592
- Leen AM, Heslop HE, Brenner MK. Antiviral T-cell therapy. Immunol Rev 2014;258(1):12-29
- Toth K, Ying B, Tollefson AE, et al. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. Viruses 2015;7(3):1409-28
- Ying B, Tollefson AE, Spencer JF, et al. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. Antimicrob Agents Chemother 2014;58(12):7171-81